IP Library Granted Patent US 8,679,816
Granted Patent B2
US 8,679,816 · App. 13/321,928 · Granted Mar 25, 2014

Cellulase variants with improved expression, activity and stability, and use thereof

Inventors: Wolfgang Aehle (Zwingenberg, DE); Richard R. Bott (Burlingame, CA); Benjamin Bower (Newark, CA); Jonathan Caspi (Sunnyvale, CA); David A. Estell (San Francisco, CA); Frits Goedegebuur (Vlaardingen, NL); Ronaldus W. J. Hommes (Haarlem, NL); Thijs Kaper (Half Moon Bay, CA); Bradley Kelemen (Menlo Park, CA); Slavko Kralj (Oegstgeest, NL); Johan Van Lieshout (Utrecht, NL); Igor Nikolaev (Noordwijk, NL); Sander Van Stigt Thans (Zevenbergen, NL); Louise Wallace (Palo Alto, CA); Gudrun Vogtentanz (Sunnyvale, CA); Mats Sandgren (Uppsala, SE)
Assignee: Danisco US Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,679,816
App. No.
13/321,928
Granted
Mar 25, 2014
Kind
B2
Abstract

The present disclosure relates to cellulase variants. In particular the present disclosure relates to cellulase variants having improved expression, activity and/or stability. Also described are nucleic acids encoding the cellulase variants, compositions comprising the cellulase variants, and methods of use thereof.

Claims (10)

1. A recombinant cellulase variant, wherein the variant is a mature form having cellulase activity and comprising a substitution at position 362, wherein the position is numbered by correspondence with the amino acid sequence of a reference cellobiohydrolase II (CBH2) set forth as SEQ ID NO:3, wherein the variant is derived from a parent cellulase whose amino acid sequence is at least 90% identical to SEQ ID NO:3.

2. The recombinant cellulase variant of claim 1 , wherein the variant comprises a further substitution at one or more further positions selected from 98 and 343, wherein the further positions are numbered by correspondence with the amino acid sequence of the reference cellobiohydrolase II (CBH2) set forth as SEQ ID NO:3.

3. A recombinant cellulase variant, wherein the variant is a mature form having cellulase activity and comprising a substitution at one or more positions selected from the group consisting of: 98 and 343, wherein the positions are numbered by correspondence with the amino acid sequence of a reference cellobiohydrolase II (CBH2) set forth as SEQ ID NO:3, and wherein when the cellulase variant consists of a single substitution, the single substitution is not P98L, wherein the variant is derived from a parent cellulase whose amino acid sequence is at least 90% identical to SEQ ID NO:3.

4. The recombinant cellulase variant of claim 3 , wherein the variant comprises a further substitution at position 362, wherein the further positions are numbered by correspondence with the amino acid sequence of the reference cellobiohydrolase II (CBH2) set forth as SEQ ID NO:3.

5. A recombinant cellulase variant comprising a glutamine at position 98, and a substitution selected from the group consisting of S343Q and Q362I, wherein the positions are numbered by correspondence with the amino acid sequence of the reference cellobiohydrolase II (CBH2) set forth as SEQ ID NO:3, wherein the variant is derived from a parent cellulase whose amino acid sequence is at least 90% identical to SEQ ID NO:3.

6. A recombinant cellulase variant comprising a glutamine at position 343, and a substitution of Q362I, wherein the positions are numbered by correspondence with the amino acid sequence of the reference cellobiohydrolase II (CBH2) set forth as SEQ ID NO:3, wherein the variant is derived from a parent cellulase whose amino acid sequence is at least 90% identical to SEQ ID NO:3.

7. A recombinant cellulase variant, wherein the variant is a mature form having cellulase activity and comprising a substitution selected from the group consisting of 98, 362, and both 98 and 362, wherein the cellulase variant comprises:

Proline, leucine or glutamine at position 98;

glutamine, isoleucine or leucine at position 362;

wherein the positions are numbered by correspondence with the amino acid sequence of the reference cellobiohydrolase II (CBH2) set forth as SEQ ID NO:3, and wherein when the cellulase variant consists of a single substitution, the single substitution is not P98L substitution, wherein the variant is derived from a parent cellulase whose amino acid sequence is at least 90% identical to SEQ ID NO:3.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2018
From: DANISCO US INC.
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 046571/0959 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2014
From: AEHLE, WOLFGANG; BOTT, RICHARD R.; BOWER, BENJAMIN; CASPI, JONATHAN; ESTELL, DAVID A.; GOEDEGEBUUR, FRITS; HOMMES, RONALDUS W. J.; KAPER, THIJS; KELEMEN, BRADLEY; KRALJ, SLAVKO; VAN LIESHOUT, JOHAN; NIKOLAEV, IGOR; VAN STIGT THANS, SANDER; WALLACE, LOUISE; VOGTENTANZ, GUDRUN; SANDGREN, MATS
To: DANISCO US INC.
Reel/Frame 032106/0309 →
Continuity (2)
Provisional Application 61183959 · Jun 3, 2009
Related Publication 20120135500A1 · May 31, 2012